AZD-1480
Code | Size | Price |
---|
TAR-T3069-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3069-5mg | 5mg | £112.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3069-1mL | 1 mL * 10 mM (in DMSO) | £114.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3069-10mg | 10mg | £136.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3069-25mg | 25mg | £185.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
AZD1480 is a novel ATP-competitive JAK2 inhibitor (IC50: 0.26 nM), selectivity act against Tyk2 and JAK3, and to a smaller extent against JAK1. AZD1480 has been used in trials studying the treatment of Solid Malignancies, Post-Polycythaemia Vera, Primary Myelofibrosis (PMF), and Essential Thrombocythaemia Myelofibrosis.
CAS:
935666-88-9
Formula:
C14H14ClFN8
Molecular Weight:
348.77
Pathway:
JAK/STAT signaling; Stem Cells; Angiogenesis; Chromatin/Epigenetic
Purity:
0.9855
SMILES:
C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1
Target:
JAK
References
1. E Derenzini, et al. Blood Cancer J, 2011, 1(12), e46.
2. Scuto A, et al. Leukemia, 2011, 25(3), 538-50.
3. McFarland BC,et al. Cancer Ther, 2011, 10(12), 2384-93.
4. Xin H, et al. Cancer Res, 2011, 71(21), 6601-10.
5. Hedvat M, et al. Cancer Cell, 2009, 16(6), 487-97.
6. Ni J, et al. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 Jan;19(1):22-30.
7. Yang, Tianfeng, Xianpeng Shi, Yuan Kang, Man Zhu, Mengying Fan, Dongdong Zhang, and Yanmin Zhang. Novel compounds TAD-1822-7-F2 and F5 inhibited HeLa cells growth through the JAK/Stat signaling pathway [J]. Biomedicine & Pharmacotherapy . 2018 Jul;103:118-126.